The genomic, transcriptomic, and immunologic landscape in solid tumors expressing leukocyte immunoglobulin like receptor B2

Authors:

Sandra Jones, Harris Krause, Jose Noy, Samuel Kareff, Asaad Trabolsi, Andrew Elliott, Alex Farrell, Balazs Halmos, Patrick Ma, Wafik El- Deiry, Ari Vanderwalde, Milan Radovich, George Sledge, Gilberto Lopes

Study Highlights

  • The genomic landscape of high versus low LILRB2 expressors varied widely by cancer type.
  • LILRB2 expression was associated with biomarkers of response to immunotherapy such as PD-L1+ and an increased proportion of T cellinflamed tumors.
  • High expression of LILRB2 was associated with improved time on treatment with pembrolizumab in Methods NSCLC.

Conclusions

  • These data suggest that PDAC, NSCLC and UC tumors could potentially benefit from a combination of immune checkpoint inhibitors and LILRB2- blocking antibodies.
Download Publication